Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Input submissions will be received through 13:00, July 15th.
The Haute Autorité de Santé (HAS), National Institute for Health and Care Excellence (NICE) & the Croatian Institute for Public Health (HZJZ) are pleased to share the following WP5 strand B draft outputs for an 8 week public consultation: REQueST (Registry Evaluation and Quality Standards Tool): a tool that is built upon the results of […]
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with. lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. To find out […]
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. To find out more about how patient input can contribute to this assessment, please read further here. Input is greatly appreciated […]
Find public consultation HERE
Patient group input requested for a new Joint Assessment on a medicinal product for Diabetes Type 1 – Closing August 3
EUnetHTA Joint Production is pleased to announce the launch of the REA for Sotagliflozin for Type 1 diabetes mellitus (PTJA04) For this specific assessment on a medicinal product for Diabetes Type 1, an ‘open call for patient group submission‘ is used. We are seeking for European and national patient organisations to provide an organisational perspective […]
Following on the successful launch of the JA3 procedures for European Network for Health Technology Assessment (EUnetHTA) Early Dialogues (ED) for Pharmaceutical products, EUnetHTA is pleased to announce the future launch of EDs for Medical Devices. The procedure is a single gateway for early dialogues with European HTA bodies on their evidence-generation plans for medical […]
The EC-EUnetHTA Forum “European cooperation on HTA: what’s next?” co-organised by the European Commission and the EUnetHTA Joint Action 3 was the first meeting between all 79 EUnetHTA partner organisations and the broader HTA stakeholder community. The event was well attended and the lively discussions were structured around three panels: Panel 1: EU cooperation on […]
We are happy to announce that the third Core HTA produced within the EUnetHTA Joint Action 2 Work Package 4 is available for public feedback. The topic assessed is “Structured telephone support (STS) for adult patients with chronic heart failure” This consultation will take place between November 10th and November 26th, 2015. Objective of public […]